文章预览
SCI 14 December 2024 Minimal residual disease as a target for liquid biopsy in patients with solid tumours (Nat Rev Clin Oncol;IF：81.1) Correspondence to: pantel@uke.de; c-panabieres@chu-montpellier.fr Pantel K, Alix-Panabières C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2024. Abstract 摘要 Metastasis is the leading cause of cancer-related death in patients with solid tumours. Current imaging technologies are not sufficiently sensitive to detect minimal residual disease (MRD; also known as measurable or molecular residual disease) after initial surgery or chemotherapy, pointing to the need for more sensitive tests to detect remaining traces of cancer in the body. Liquid biopsy, or the analysis of tumour-derived or tumour-induced cells or cellular products in the blood or other body fluids, has opened a new diagnostic avenue to detect and monitor MRD. Liquid biopsy is already used in clinical decision making for pati
………………………………
